Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.


NDAQ:INM - Post by User

Bullboard Posts
Comment by Alltimeon Jan 11, 2018 7:43pm
171 Views
Post# 27338003

RE:RE:RE:RE:RE:RE:Not to bad!!

RE:RE:RE:RE:RE:RE:Not to bad!!
Lets look at the situation from an investor point of view. If you are a daily trader, then the is not for you. You will sell regardless of how good the company to make the quick buck. Daily trading and long-term investing are different types of strategy. Everyone is making a big deal of Adams and a few of them selling. Let me tell you this is a scheduled sell. Why? because under the SEC rule 10b-1 states: Under Rule 10b5-1, directors and other major insiders in the company large shareholders, officers and others who are able to access material nonpublic information (MNPI) are able to establish a written plan that details when they will be able to buy or sell shares at a predetermined time on a scheduled basis. It is established this way so that the insiders have the ability to buy or sell shares when they are not in the vicinity of MNPI. This also allows companies to utilize 10b5-1 plans in large stock buybacks. Read more: Rule 10b5-1 https://www.investopedia.com/terms/r/rule-10b5-1.asp#ixzz53p0XPksh Follow us: Investopedia on Facebook. As you read, they are "predetermined" sell. If these people are manipulating the price, then why would you file the transaction for everyone to see? Why? Because its the law! Do people who post here think that those people that sold because of "inside information" risk going to prison for 200k-500k. Will they ruin their lifelong career for that price? By the way file the transaction for everyone to see as evidence. So before we post and troll, let's do some "due diligence". I am sure Adams and Hozzaine are hating themselves right now to sell shares at this point. However, they have no option or they will be charge for insider trading. Less A rule established by the Securities Exchange Commission (SEC) that allows insiders of publicly traded corporations to set up a trading plan for selling stocks they own. Rule 10b5-1 allows major holders to sell a predetermined number of shares at a p A rule established by the Securities Exchange Commission (SEC) that allows insiders of publicly traded corporations to set up a trading plan for selling stocks they own. Rule 10b5-1 allows major holders to sell a predetermined number of shares at a p A rule established by the Securities Exchange Commission (SEC) that allows insiders of publicly traded corporations to set up a trading plan for selling stocks they own. Rule 10b5-1 allows major holders to sell a predetermined number of shares at a p www.investopedia.com.
Bullboard Posts